{"entity":{"id":"nct04499053","kind":"trial","name":"Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer","aka":[],"tldr":"A phase 2 trial of durvalumab and tremelimumab in lung cancer, run by Georgetown University, now recruiting.","summary":"Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer is a phase 2, interventional study registered as NCT04499053 by Georgetown University, with a registry enrolment figure of 18 participants, started 2020-12-09 and due to reach its primary completion in 2027-02. Interventions recorded: Durvalumab; Tremelimumab. Conditions listed: Carcinoma, Non-Small Cell Lung. Primary outcome: Adverse Events; Radiological Response. Lung eligibility wording from the registry: \"Patients with stage IV NSCLC who had undergone no previous systemic therapy for stage IV disease\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT04499053","url":"https://clinicaltrials.gov/study/NCT04499053"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["durvalumab","tremelimumab"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04499053","phase":"2","setting":"A Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer","sponsor":"Georgetown University","enrolled":18,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04499053/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"},{"id":"tremelimumab","kind":"drug","name":"Tremelimumab","route":"/drugs/tremelimumab/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}